ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes
Taselisib is a potent β‐sparing phosphatidylinositol 3‐kinase (PI3K) inhibitor that, with endocrine therapy, improves outcomes in phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (PIK3CA)‐mutated (PIK3CAmut) advanced breast cancer. To understand alterations associated with resp...
Main Authors: | Jessica W. Chen, William Jacot, Javier Cortés, Ian E. Krop, Susan Dent, Nadia Harbeck, Michelino De Laurentiis, Véronique Diéras, Young‐Hyuck Im, Thomas J. Stout, Frauke Schimmoller, Heidi M. Savage, Katherine E. Hutchinson, Timothy R. Wilson |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-10-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13416 |
Similar Items
-
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers
by: Katherine E. Hutchinson, et al.
Published: (2023-04-01) -
The Influence of Body Condition on the Stopover Ecology of Least Sandpipers in the Lower Mississippi Alluvial Valley during Fall Migration
by: Sarah E. Lehnen, et al.
Published: (2007-12-01) -
Mitochondrial genome analysis of the spoon-billed sandpiper (Eurynorhynchus pygmeus)
by: Hey-Sook Joen, et al.
Published: (2017-01-01) -
[Sightings of Purple Sandpiper Calidris maritima in Italy, a review]
by: Maurizio Sighele
Published: (2018-12-01) -
Target therapy of luminal HER2-negative advanced breast cancer with PIK3CA mutation: combination of alpelisib plus fulvestrant in real clinical practice
by: D. A. Filonenko, et al.
Published: (2021-12-01)